Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

The Next Bristol/ImClone? “Standstill” Provisions Complicate Other Deals

  • News

Executive Summary

Roche and Bristol-Myers Squibb have everyone wondering who will be the next company to buy out its biotech partner

You may also be interested in...



Groundhog Day For Byetta, GLP-1 Class: Is Regulatory Winter Nearly Over?

Sponsors of GLP-1 diabetes therapies and their investors are eagerly awaiting spring for greater clarity about the prospects of the antidiabetic class

Groundhog Day For Byetta, GLP-1 Class: Is Regulatory Winter Nearly Over?

Sponsors of GLP-1 diabetes therapies and their investors are eagerly awaiting spring for greater clarity about the prospects of the antidiabetic class

Amylin Speculation Intensifies, Part 2: Activist Shareholders Grow Restless

Eastbourne Capital says it wants Amylin to find a buyer. Is Lilly ready for another billion dollar deal?

Table

View full table

Related Content

Pink Sheet
Pink Sheet
In Vivo
Pink Sheet
Pink Sheet
Tags:
Latest Headlines

ACA Ruling Is Double Whammy For PrEP Coverage, With Contraception And Vaccines Still At Risk

The Power Of The Public: Isotretinoin iPLEDGE Advisory Cmte. Is Case Study In An Effective OPH

Teva’s ‘Skinny Label’ Dispute Edges Toward Supreme Court With Government’s Backing

iPLEDGE REMS: US FDA Advisory Cmte. Supports Relaxing Restrictions But Wants More Data

See All
UsernamePublicRestriction

Register

PS050080

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By